pSivida Corp. (NASDAQ: PSDV), a specialty pharmaceutical company that is a leader in developing sustained release drugs for treatment of back-of-the-eye diseases, will present at two upcoming investor conferences in September. pSivida will present at the Rodman & Renshaw Annual Global Investment Conference being held at the Millennium Broadway Hotel in New York on Tuesday, September 10 at 12:05 p.m. This presentation will be webcast and can be found at the following link: http://wsw.com/webcast/rrshq23/PSDV. Follow the official Rodman & Renshaw handle on Twitter @rodman_2013 and use #rodman2013 for conference information and updates. pSivida will also present at the Stifel Nicolaus Healthcare Conference being held at the Four Seasons Boston Hotel, in the Winthrop Room, on Thursday, September 12 at 11:30 a.m. and will also be webcast: http://www.veracast.com/webcasts/stifel/healthcare2013/98207674667.cfm. All times are Eastern. About pSivida pSivida Corp., headquartered in Watertown, MA, develops tiny, sustained release, drug delivery products designed to deliver drugs at a controlled and steady rate for months or years. pSivida is currently focused on treatment of chronic diseases of the back of the eye utilizing its core technology systems, Durasert™ and BioSilicon™. The injectable, sustained release micro-insert ILUVIEN® for the treatment of chronic DME considered insufficiently responsive to available therapies, licensed to Alimera Sciences, Inc., has received marketing authorization in Austria, France, Germany, Portugal, Spain and the U.K. and is awaiting authorization in Italy. Alimera has resubmitted the New Drug Application for ILUVIEN for DME to the U.S. Food and Drug Administration. pSivida plans to institute pivotal Phase III clinical trials for the treatment of posterior uveitis, a chronic back-of-the-eye disease, with the same micro-insert as ILUVIEN for DME. An investigator-sponsored clinical trial is ongoing for an injectable, bioerodible micro-insert to treat glaucoma and ocular hypertension. pSivida's FDA-approved Retisert® licensed to Bausch & Lomb Incorporated provides long-term, sustained drug delivery to treat posterior uveitis.